These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 27226714

  • 1. Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis.
    Zou H, Li L, Garcia Carcedo I, Xu ZP, Monteiro M, Gu W.
    Int J Nanomedicine; 2016; 11():1947-58. PubMed ID: 27226714
    [Abstract] [Full Text] [Related]

  • 2. Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis.
    Hu Y, Zhang K, Zhu X, Zheng X, Wang C, Niu X, Jiang T, Ji X, Zhao W, Pang L, Qi Y, Li F, Li L, Xu Z, Gu W, Zou H.
    Int J Nanomedicine; 2021; 16():2173-2186. PubMed ID: 33758505
    [Abstract] [Full Text] [Related]

  • 3. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M.
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
    [Abstract] [Full Text] [Related]

  • 4. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li Z, Wang J, Li B, Hu Y, Dong B, Shen L, Ji J, Gao J, Zhang X.
    Cell Death Dis; 2018 Jan 26; 9(2):123. PubMed ID: 29374144
    [Abstract] [Full Text] [Related]

  • 5. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A, Li H, Li R, Lu L, Wu X.
    Oncol Rep; 2018 Oct 26; 40(4):2353-2362. PubMed ID: 30066933
    [Abstract] [Full Text] [Related]

  • 6. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 26; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 7. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
    Chen YH, Wei MF, Wang CW, Lee HW, Pan SL, Gao M, Kuo SH, Cheng AL, Teng CM.
    Cancer Lett; 2015 Feb 28; 357(2):582-90. PubMed ID: 25497009
    [Abstract] [Full Text] [Related]

  • 8. PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.
    Chen J, Shao R, Li F, Monteiro M, Liu JP, Xu ZP, Gu W.
    Clin Exp Pharmacol Physiol; 2015 Dec 28; 42(12):1317-26. PubMed ID: 26399781
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Dec 28; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 10. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 11. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 12. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
    Chen L, Jin T, Zhu K, Piao Y, Quan T, Quan C, Lin Z.
    Oncotarget; 2017 Feb 14; 8(7):11937-11949. PubMed ID: 28060760
    [Abstract] [Full Text] [Related]

  • 13. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.
    Zhang CΗ, Awasthi N, Schwarz MA, Schwarz RE.
    Int J Oncol; 2013 Nov 14; 43(5):1627-35. PubMed ID: 24042258
    [Abstract] [Full Text] [Related]

  • 14. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
    Piao J, Chen L, Quan T, Li L, Quan C, Piao Y, Jin T, Lin Z.
    Oncotarget; 2016 Sep 13; 7(37):60169-60180. PubMed ID: 27507059
    [Abstract] [Full Text] [Related]

  • 15. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
    Liang M, Lv J, Chu H, Wang J, Chen X, Zhu X, Xue Y, Guan M, Zou H.
    J Dermatol Sci; 2014 Nov 13; 76(2):104-11. PubMed ID: 25258031
    [Abstract] [Full Text] [Related]

  • 16. Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
    Hugle M, Fulda S.
    Cancer Lett; 2015 Apr 28; 360(1):1-9. PubMed ID: 25637161
    [Abstract] [Full Text] [Related]

  • 17. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
    Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA.
    Oncotarget; 2015 Nov 03; 6(34):35202-17. PubMed ID: 26460954
    [Abstract] [Full Text] [Related]

  • 18. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
    Schult C, Dahlhaus M, Glass A, Fischer K, Lange S, Freund M, Junghanss C.
    Anticancer Res; 2012 Feb 03; 32(2):463-74. PubMed ID: 22287733
    [Abstract] [Full Text] [Related]

  • 19. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.
    J Urol; 2014 Jan 03; 191(1):227-34. PubMed ID: 23954373
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
    Qian XJ, Li YT, Yu Y, Yang F, Deng R, Ji J, Jiao L, Li X, Wu RY, Chen WD, Feng GK, Zhu XF.
    Oncotarget; 2015 Mar 10; 6(7):5134-46. PubMed ID: 25762617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.